Mitogen-activated protein kinase antisense oligonucleotide inhibits the growth of human lung cancer cells

International Journal of Oncology

Volumn 14, Issue 3, 1999, Pages 461-469

  Nishio, Kazuto ^a   Fukuoka, Kazuya ^a   Fukumoto, Hisao ^a   Sunami, Toshihiko ^a   Iwamoto, Yasuo ^a   Suzuki, Toshihiro ^a   Usuda, Jitsuo ^a   Saijo, Nagahiro ^a  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

Author keywords

Antisense oligonucleotide; Apoptosis; MAPK; Non small cell lung cancer cells

Indexed keywords

ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; DIGITONIN; DNA; PROTEIN KINASE (CALCIUM,CALMODULIN);

ANIMAL; APOPTOSIS; ARTICLE; BIOSYNTHESIS; CELL CULTURE; CELL CYCLE; CELL DIVISION; CELL MEMBRANE PERMEABILITY; CELL STRAIN 3T3; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; GENETICS; HUMAN; LUNG TUMOR; METABOLISM; MOUSE; PATHOLOGY;

3T3 CELLS; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CA(2+)-CALMODULIN DEPENDENT PROTEIN KINASE; CELL CYCLE; CELL DIVISION; CELL MEMBRANE PERMEABILITY; DIGITONIN; DNA, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; LUNG NEOPLASMS; MICE; OLIGONUCLEOTIDES, ANTISENSE; TUMOR CELLS, CULTURED;

EID: 0033090990     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.14.3.461     Document Type: Article

References (31)

1. Hamel E: Antimitotic natural products and their interactions with tubulin. Med Res Rev 16: 207-231, 1996.
2. Correia JJ: Effects of antimitotic agents on tubulin-nucleotide interactions. Pharmacol Ther 52: 127-147, 1991.
3. Raffaelli N, Yamauchi PS and Purich DL: Microtubule-associated protein autophosphorylation alters in vitro microtubule dynamic instability. FEBS Lett 296: 21-24, 1992.
4. Marte BM, Graus-Porta D, Jeschke M, Fabbro D, Hynes NE and Taverna D: NDF/heregulin activates MAP kinase and p70/p85 S6 kinase during proliferation or differentiation of mammary epithelial cells. Oncogene 10: 167-175, 1995.
5. Lange CC, Pleiman CM, Gardner AM, Blumer KJ and Johnson GL: A divergence in the MAP kinase regulatory network defined by MEK kinase and Raf. Science 260: 315-319, 1993.
6. Williams NG, Roberts TM and Li P: Both p21ras and pp60v-src are required, but neither alone is sufficient, to activate the Raf-1 kinase. Proc Natl Acad Sci USA 89: 2922-2926, 1992.
7. Holmes FA, Walters RS, Theriault RL, Forman AD, Newton LK, Raber MN, Buzdar AU, Frye DK and Hortobagyi GN: Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 83: 1797-1805, 1991.
8. Nishio K, Arioka H, Ishida T, Fukumoto H, Kurokawa H, Sata M, Ohata M and Saijo N: Enhanced interaction between tubulin and microtubule-associated protein 2 via inhibition of MAP kinase and CDC2 kinase by paclitaxel. Int J Cancer 63: 688-693, 1995.
9. Sivaraman VS, Wang H-Y, Nuovo GJ and Malbon CC: Hyperexpession of mitogen-activated protein kinase in human breast cancer. J Clin Invest 99: 1478-1483, 1997.
10. Johnson GL: Signal transduction abnormalities in cancer; mitogen-activated proteinkinase regulation is altered in breast cancer. J Clin Invest 99: 1463-1464, 1997.
11. Niimi S, Nakagawa K, Yokota J, Tsunokawa Y, Nishio K, Terashima Y, Shibuya M, Terada M and Saijo N: Resistance to anticancer drugs in NIH3T3 cells transfected with c-myc and/or c-H-ras genes. Br J Cancer 63: 237-241, 1991.
12. Sale EM, Atkinson PG and Sale GJ: Requirement of MAP kinase for differentiation of fibroblasts to adipocytes, for insulin activation of p90 S6 kinase and for insulin or serum stimulation of DNA synthesis. EMBO J 14: 674-684, 1995.
13. Her JH, Wu J, Rall TB, Sturgill TW and Weber MJ: Sequence of pp42/MAP kinase, a serine/threonine kinase regulated by tyrosine phosphorylation. Nucleic Acids Res 19: 3743, 1991.
14. Mosmann T: Rapid colorimetric assay for cellular growth and survial: application to proliferation and cytotoxicity assay. J Immunol Methods 65: 55-63, 1983.
15. Nishio K, Sugimoto Y, Fujiwara Y, Ohmori T, Morikage T, Takeda Y, Ohata M and Saijo N: Phospholipase C-mediated hydrolysis of phosphatidylcholine is activated by cis-diammine-dichloroplatinum(II). J Clin Invest 89: 1622-1628, 1992.
16. Lee YS, Nishio K, Ogasawara H, Funayama Y, Ohira T and Saijo N: In vitro cytotoxicity of a novel antitumor antibiotic, spicamycin derivative, in human lung cancer cell lines. Cancer Res 55: 1075-1079, 1995.
17. Hunter T: Protein kinases and phosphatases: the yin and yang of protein phosphorylation and signaling. Cell 80: 225-236, 1995.
18. Cowley S, Paterson H, Kemp P and Marshall CJ: Activation of MAP kinase kinase is necessary and sufficient for PC12 differentiation and for transformation of NIH 3T3 cells. Cell 77: 841-852, 1994.
19. Ohira T, Nishio K, Kanzawa F, Ishida T, Ohe Y, Arioka H, Funayama Y, Ogasawara H, Kato H and Saijo N: Hypersensitivity of NIH3T3 cells transformed by H-ras gene to DNA-topoisomerase-I inhibitors. Int J Cancer 67: 702-708, 1996.
20. Dudley DT, Pang L, Decker SJ, Bridges AJ and Saltiel AR: A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc Natl Acad Sci USA 92: 7686-7689, 1995.
21. Alessi DR, Cuenda A, Cohen P, Dudley DT and Saltiel AR: PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo. J Biol Chem 270: 27489-27494, 1995.
22. Ohta S, Nishio K, Kubota N, Ohmori T, Funayama Y, Ohira T, Nakajima H, Adachi M and Saijo N: Characterization of a taxol-resistant human small-cell lung cancer cell line. Jpn J Cancer Res 85: 290-297, 1994.
23. Payne DM, Rossomando AJ, Martino P, Erickson AK, Her JH, Shabanowitz J, Hunt DF, Weber MJ and Sturgill TW: Identification of the regulatory phosphorylation sites in pp42/mitogen-activated protein kinase (MAP kinase). EMBO J 10: 885-892, 1991.
24. Sturgill TW, Ray LB, Erikson E and Maller JL: Insulin-stimulated MAP-2 kinase phosphorylates and activates ribosomal protein S6 kinase II. Nature 334: 715-718, 1988.
25. Hill CS and Treisman R: Transcriptional regulation by extracellular signals: mechanisms and specificity. Cell 80: 199-211, 1995.
26. Thomas G: MAP kinase by any other name smells just as sweet. Cell 68: 3-6, 1992.
27. Xia Z, Dickens M, Raingeaud J, Davis RJ and Greenberg ME: Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 270: 1326-1331, 1995.
28. Stearns ME, Wang M, Tew KD and Binder LI: Estramustine binds a map-1-like protein to inhibit microtubule assembly in vitro and disrupt microtubule organization in du 145 cells. J Cell Biol 107: 2647-2656, 1988.
29. Mareel MM, Storme GA, Dragonetti CH, De Bruyne GK, Hartley-Asp B, Segers JL and Rabaey ML: Antiinvasive activity of estramustine on malignant MO4 mouse cells and on DU-145 human prostate carcinoma cells in vitro. Cancer Res 48: 1842-1849, 1988.
30. Luduena RF, Fellous A, McManus L, Jordan MA and Nunez J: Contrasting roles of tau and microtubule-associated protein 2 in the vinblastine-induced aegregation of brain tubulin. J Biol Chem 259: 12890-12898, 1984.
31. Colombo R and Milzani A: How does doxorubicin interfere with actin polymerization? Biochim Biophys Acta 968: 9-16, 1988.